|
1
|
Wallace KL, Riedel AA, Joseph-Ridge N and
Wortmann R: Increasing prevalence of gout and hyperuricemia over 10
years among older adults in a managed care population. J Rheumatol.
31:1582–1587. 2004.PubMed/NCBI
|
|
2
|
Choi HK and Ford ES: Prevalence of the
metabolic syndrome in individuals with hyperuricemia. Am J Med.
120:442–447. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kramer HM and Curhan G: The association
between gout and nephrolithiasis: the National Health and Nutrition
Examination on Survey III, 1988–1994. Am J Kidney Dis. 40:37–42.
2002.PubMed/NCBI
|
|
4
|
Smith E, Hoy D, Cross M, et al: The global
burden of gout: estimates from the Global Burden of Disease 2010
study. Ann Rheum Dis. 73:1470–1476. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Smith EU, Díaz-Torné C, Perez-Ruiz F and
March LM: Epidemiology of gout: an update. Best Pract Res Clin
Rheumatol. 24:811–827. 2010. View Article : Google Scholar
|
|
6
|
Miao Z, Li C, Chen Y, et al: Dietary and
lifestyle changes associated with high prevalence of hyperuricemia
and gout in the Shandong coastal cities of Eastern China. J
Rheumatol. 35:1859–1864. 2008.PubMed/NCBI
|
|
7
|
Doherty M: New insights into the
epidemiology of gout. Rheumatology (Oxford). 48(Suppl 2): ii2–ii8.
2009. View Article : Google Scholar
|
|
8
|
Roddy E, Zhang W and Doherty M: The
changing epidemiology of gout. Nat Clin Pract Rheumatol. 3:443–449.
2007. View Article : Google Scholar
|
|
9
|
Lawrence RC, Helmick CG, Arnett FC, et al:
Estimates of the prevalence of arthritis and selected
musculoskeletal disorders in the United States. Arthritis Rheum.
41:778–799. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Helmick CG, Felson DT, Lawrence RC, et al:
Estimates of the prevalence of arthritis and other rheumatic
conditions in the United States. Part I. Arthritis Rheum. 58:15–25.
2008. View Article : Google Scholar
|
|
11
|
Kim SY, De Vera MA and Choi HK: Gout and
mortality. Clin Exp Rheumatol. 26(5 Suppl 51): S115–S119.
2008.PubMed/NCBI
|
|
12
|
Luk AJ and Simkin PA: Epidemiology of
hyperuricemia and gout. Am J Manag Care. 11(15 Suppl): S435–S442.
2005.PubMed/NCBI
|
|
13
|
Arromdee E, Michet CJ, Crowson CS,
O’Fallon WM and Gabriel SE: Epidemiology of gout: is the incidence
rising? J Rheumatol. 29:2403–2406. 2002.PubMed/NCBI
|
|
14
|
Lawrence RC, Felson DT, Helmick CG, et al:
Estimates of the prevalence of arthritis and other rheumatic
conditions in the United States. Part II. Arthritis Rheum.
58:26–35. 2008. View Article : Google Scholar
|
|
15
|
Hoskison KT and Wortmann RL: Management of
gout in older adults: barriers to optimal control. Drug Aging.
24:21–36. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cheng HF and Harris RC: Renal effects of
non-steroidal anti-inflammatory drugs and selective
cyclooxygenase-2 inhibitors. Curr Pharm Des. 11:1795–1804. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
White WB: Cardiovascular risk,
hypertension, and NSAIDs. Curr Rheumatol Rep. 9:36–43. 2007.
View Article : Google Scholar
|
|
18
|
Soleimani M: Dietary fructose, salt
absorption and hypertension in metabolic syndrome: towards a new
paradigm. Acta Physiol (Oxf). 201:55–62. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Keenan RT, O’Brien WR, Lee KH, et al:
Prevalence of contraindications and prescription of pharmacologic
therapies for gout. Am J Med. 124:155–163. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chernyshev AL, Filimonov RM, Karasev AV,
et al: Combined treatment including ozonotherapy of patients with
viral hepatitis. Vopr Kurortol Fizioter Lech Fiz Kult. 3:19–22.
2008.(In Russian).
|
|
21
|
De Monte A, van der Zee H and Bocci V:
Major ozonated autohemotherapy in chronic limb ischemia with
ulcerations. J Altern Complement Med. 11:363–367. 2005.PubMed/NCBI
|
|
22
|
Bocci V, Borrelli E, Travagli V and
Zanardi I: The ozone paradox: ozone is a strong oxidant as well as
a medical drug. Med Res Rev. 29:646–682. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ripamonti CI, Cislaghi E, Mariani L and
Maniezzo M: Efficacy and safety of medical ozone (O(3)) delivered
in oil suspension applications for the treatment of osteonecrosis
of the jaw in patients with bone metastases treated with
bisphosphonates: Preliminary results of a phase I-II study. Oral
Oncol. 47:185–190. 2011. View Article : Google Scholar
|
|
24
|
Zhang W, Doherty M, Pascual E, Bardin T,
et al: EULAR evidence based recommendations for gout. Part I:
Diagnosis Report of a task force of the Standing Committee for
International Clinical Studies Including Therapeutics (ESCISIT).
Ann Rheum Dis. 65:1301–1311. 2006. View Article : Google Scholar
|
|
25
|
Bocci V: Ozone as Janus: this
controversial gas can be either toxic or medically useful.
Mediators Inflamm. 13:3–11. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bocci V, Valacchi G, Corradeschi F, et al:
Studies on the biological effects of ozone: 7. Generation of
reactive oxygen species (ROS) after exposure of human blood to
ozone. J Biol Regul Homeost Agents. 12:67–75. 1998.PubMed/NCBI
|
|
27
|
Hoffstein S and Weissmann G: Mechanisms of
lysosomal enzyme release from leukocytes. IV Interaction of
monosodium urate crystals with dogfish and human leukocytes.
Arthritis Rheum. 18:153–165. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kozin F, Ginsberg MH and Skosey JL:
Polymorphonuclear leukocyte responses to monosodium urate crystals:
modification by adsorbed serum proteins. J Rheumatol. 6:519–526.
1979.PubMed/NCBI
|
|
29
|
Nuki G: Colchicine: its mechanism of
action and efficacy in crystal-induced inflammation. Curr Rheumatol
Rep. 10:218–227. 2008. View Article : Google Scholar : PubMed/NCBI
|
